We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avodart sNDA for Prostate Cancer Withdrawn by GSK
Avodart sNDA for Prostate Cancer Withdrawn by GSK
November 25, 2009
GlaxoSmithKline (GSK) is withdrawing its sNDA for Avodart (dutasteride) to reduce the risk of developing prostate cancer but plans to resubmit the application
with revised data soon.